ArticleJournal of biomedical optics2025
Versatile and comprehensive hyperspectral imaging tool for molecular neuronavigation: a case study on cerebral gliomas.
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reconstruction Accuracy vs. Discriminative Power: Spectral Unmixing Performance in Brain Tissue Hyperspectral Imaging.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Accurate and timely characterization of brain tumors remains a major challenge in neurosurgery. Current intraoperative guidance relies on preoperative imaging modalities such as magnetic resonance imaging, positron emission tomography, or computed tomography, which are essential for surgical planning but become less reliable during surgery due to brain shift. Furthermore, postoperative tumor classification depends on histopathology, which requires weeks and can delay treatment decisions. No existing tool offers real-time, label-free, and spatially resolved biomolecular information to support both intraoperative guidance and early tissue assessment. Aim: We developed HyperProbe1.1 (HP1.1), a hyperspectral imaging system designed to acquire comprehensive molecular and metabolic information from brain tissue without the need for contrast agents or staining. Approach: HP1.1 captures reflectance images across a broad range of narrow spectral bands, enabling spatial mapping of hemoglobin, cytochrome c oxidase, and oxygen saturation. In addition, ultraviolet-excited autofluorescence imaging provides information on metabolic cofactors - nicotinamide adenine dinucleotide and flavin adenine dinucleotide - relevant for tumor characterization. The system was validated using standardized phantoms and Results: HP1.1 demonstrated strong performance in detecting spectral features across phantoms and in distinguishing glioma tissues of different histological grades, enabling the generation of rapid and spatially resolved molecular contrast maps. Conclusions: By providing label-free, high-content, and rapid biomolecular imaging, HP1.1 represents a powerful platform for noninvasive tissue assessment in controlled experimental settings and paves the way for future intraoperative applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.